Abstract
Background Idiopathic pulmonary fibrosis (IPF) with co-existent emphysema, termed combined pulmonary fibrosis and emphysema (CPFE) may be associated with reduced FVC decline compared to non-CPFE IPF patients. We examined associations between mortality and functional measures of disease progression in two IPF cohorts.
Methods Visual emphysema extent (CPFE:non-CPFE: derivation cohort=317:183; replication cohort=358:152), scored on computed tomography imaging subgrouped CPFE patients using either a) 10%, or b) 15% visual emphysema threshold, or c) an unsupervised machine learning model considering emphysema and ILD extents. Baseline characteristics, 1-year forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLco) decline (linear mixed effects models), and their associations with mortality (multivariable Cox regression models) were compared across CPFE and non-CPFE subgroups.
Results In both IPF cohorts, CPFE patients with >10% emphysema had a greater smoking history and lower baseline DLco compared to CPFE patients with <10% emphysema. Using multivariable Cox regression analyses in patients with >10% emphysema, 1-year DLco decline was a better indicator of mortality than 1-year FVC decline. Results were maintained in patients suitable for therapeutic IPF trials.
Results were replicated in the >15% emphysema population and using unsupervised machine learning. Importantly, the unsupervised machine learning approach identified CPFE patients in whom FVC decline did not associate strongly with mortality. In non-CPFE IPF patients, 1-year FVC declines >5% and >10% showed comparable mortality associations.
Conclusion When assessing disease progression in IPF, DLco decline should be considered in patients with >10% emphysema and a >5% 1-year FVC decline threshold considered in non-CPFE IPF patients.
Competing Interest Statement
JJ reports fees from Boehringer Ingelheim, Roche, NHSX, Takeda and GlaxoSmithKline unrelated to the submitted work. JJ was supported by Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z and the NIHR Biomedical Research Centre at University College London. NM reports grant TUBITAK (EJP Rare Disease project "COCOS-IPF"), fees from Boehringer, Ingelheim, Roche, and Nobel Turkey unrelated to the submitted work. NM received support for travel to ATS 2020 and ATS 2021 from Roche, and to ERS 2020 from Actelion. TG is supported by Research Foundation-Flanders (FWO)-1S73921N. LJDS is supported by Marie Sklodowska-Curie actions post-doctoral fellowship within the European Union's Horizon Europe research and innovation programme. HJ reports fees from Boehringer ingelheim and Roche. HJ received assistance for travel to meetings from Boehringer Ingelheim and Roche. SV reports consultancy fees from Boehringer-Ingelheim and Sanofi. MV is supported by FWO (Research Flanders Foundation) Fellowship. SMJ reports fees from Astra-Zeneca, Bard1 Bioscience, Achilles Therapeutics, and Jansen unrelated to the submitted work. SMJ received assistance for travel to meetings from Astra Zeneca to American Thoracic Conference 2018 and from Takeda to World Conference Lung Cancer 2019 and is the Investigator Lead on grants from GRAIL Inc, GlaxoSmithKline plc and Owlstone. AUW reports personal fees and non-financial support from Boehringer Ingelheim, Bayer and Roche Pharmaceuticals; and personal fees from Blade, outside of the submitted work. AZ, EG, CvM, RC, TJMW, ED, RS, AA, CJB, HWvE, MD, KP, FvB, GC, AP, MV, YM, MT, AN, IS, ALY, DB, DCA, JCP, MGJ, RS, WAW report no relevant conflicts of interest.
Funding Statement
This research was funded in whole or in part by the Wellcome Trust [209553/Z/17/Z]. This project, JJ, EG, ED, SMJ and JCP were also supported by the NIHR UCLH Biomedical Research Centre, UK. MGJ, TJMW and CJB acknowledge the support of the NIHR Southampton Biomedical Research Centre. AZ was supported by CSC-UCL Joint Research Scholarship. The Australian IPF Registry is an initiative of Lung Foundation Australia and is supported by Foundation partners Boehringer Ingelheim, Roche Products Pty. Limited.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research ethics committees of: St Antonius Hospitals, Leuven University Hospital, Southampton University Hospitals, Pisa University Hospitals, University College London Hospitals, Izmir University Hospital and the Sydney Local Health District Board gave ethical approval for this work. Further approval for this retrospective study of clinically indicated pulmonary function and CT data were obtained from Leeds East Research Ethics Committee: 20/YH/0120.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Approvals are not in place to share the data produced in the present study.
